Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Common Equity: 2020-2024

Historic Common Equity for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $225.6 million.

  • Mirum Pharmaceuticals' Common Equity rose 25.87% to $292.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $292.0 million, marking a year-over-year increase of 25.87%. This contributed to the annual value of $225.6 million for FY2024, which is 9.26% down from last year.
  • As of FY2024, Mirum Pharmaceuticals' Common Equity stood at $225.6 million, which was down 9.26% from $248.7 million recorded in FY2023.
  • In the past 5 years, Mirum Pharmaceuticals' Common Equity ranged from a high of $248.7 million in FY2023 and a low of $120.2 million during FY2021.
  • In the last 3 years, Mirum Pharmaceuticals' Common Equity had a median value of $225.6 million in 2024 and averaged $205.4 million.
  • In the last 5 years, Mirum Pharmaceuticals' Common Equity plummeted by 30.15% in 2021 and then soared by 75.07% in 2023.
  • Mirum Pharmaceuticals' Common Equity (Yearly) stood at $172.1 million in 2020, then slumped by 30.15% to $120.2 million in 2021, then increased by 18.16% to $142.0 million in 2022, then skyrocketed by 75.07% to $248.7 million in 2023, then fell by 9.26% to $225.6 million in 2024.